휴온스
Financials
Valuation Metrics
휴온스's Market Cap is ₩3205B. At end of 2025 it was ₩3282B. Ranked #596 of 2,436 in KR market (top 24%), #235 of 1,649 on KOSDAQ (top 14%), #64 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 320.46B KRW | KR#596/2,436 Sec#64/234 |
| Revenue | 616.80B KRW | KR#535/2,436 Sec#23/234 |
| Net Income | 30.09B KRW | KR#508/2,436 Sec#35/234 |
| Net Assets | 408.03B KRW | KR#577/2,436 Sec#36/234 |
| Employees | 1,049 | KR#244/2,436 Sec#17/234 |
| Value | ||
| P/E | 10.65x | KR#751/2,436 Sec#39/234 |
| P/B | 0.79x | KR#1,256/2,436 Sec#73/234 |
| P/S | 0.52x | KR#967/2,436 Sec#41/234 |
| EV/EBITDA | 13.45x | KR#794/2,436 Sec#43/234 |
| FCF Yield | 7.79% | KR#722/2,436 Sec#35/234 |
| Profitability | ||
| ROE | 7.37% | KR#754/2,436 Sec#51/234 |
| Op. Margin | 5.21% | KR#903/2,436 Sec#73/234 |
| Revenue Growth | -2.72% | KR#1,600/2,436 Sec#151/234 |
| Earnings Growth | -98.46% | KR#1,368/2,436 Sec#89/234 |
| Financial Health | ||
| Debt Ratio | 162.08% | KR#1,346/2,436 Sec#154/234 |
| Total Debt | 166.70B KRW | KR#546/2,436 Sec#29/234 |
| FCF | 24.95B KRW | KR#457/2,436 Sec#27/234 |
| Cash | 55.46B KRW | KR#700/2,436 Sec#39/234 |
| Current Ratio | 1.52x | KR#1,289/2,436 Sec#140/234 |
| Net Debt/EBITDA | 3.46x | KR#988/2,436 Sec#72/234 |
| Dividend | ||
| Div. Yield | 3.66% | KR#541/2,436 Sec#23/234 |
| Div. Growth | 46.03% | KR#256/2,436 Sec#9/234 |
| Performance | ||
| 1Y Return | -2.37% | KR#768/2,436 Sec#58/234 |
| 1M Return | -2.01% | KR#1,108/2,436 Sec#105/234 |
| From 52W High | -35.54% | KR#587/2,436 Sec#41/234 |
| 1Y MDD | -40.58% | KR#537/2,436 Sec#41/234 |
| Trading | ||
| Volume | 21,522 shares | KR#1,812/2,436 Sec#184/234 |
| Foreign Own. | 15.38% | KR#308/2,436 Sec#18/234 |
| Per Share | ||
| EPS | 2,562 KRW | KR#320/2,436 Sec#22/234 |
| BPS | 31,800 KRW | KR#335/2,436 Sec#22/234 |
Company Info
Founded in 1965, the company re-listed on KOSDAQ in 2016 following a spin-off from Huons Global. It holds stakes in Huons N (health functional food company), Huons BioScience (pharmaceutical manufacturing), and PanGen (biosimilar EPO producer), which are slated for subsidiary incorporation in 2025. The professional pharmaceutical business supplies various professional pharmaceuticals domestically, while its beauty and well-being business expands into well-being pharmaceuticals, obesity treatments, medical devices, and health functional foods. Huons was established in 2016 and is headquartered in Seongnam-si, Gyeonggi-do.